Friday, 16 June 2017

Bioinformatician

Heptares Therapeutics is clinical stage company using innovative techniques in protein engineering and structure based drug design directed at G protein-coupled receptors (GPCRs). Heptares has built an exciting pipeline of new medicines across disease areas including Alzheimer's disease, migraine and cancer. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, Pfizer an…

via http://ift.tt/1puljGF

Head of Computational Chemistry

Heptares Therapeutics Ltd is clinical stage company using innovative techniques in protein engineering and structure-based drug design directed at G protein-coupled receptors (GPCRs). Heptares has built an exciting pipeline of new medicines across disease areas including Alzheimer's disease, migraine and cancer. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, Pfize…

via http://ift.tt/1puljGF

Tuesday, 16 May 2017

PhD fellowship in Ion Channel Function and Biophysics

Center for Biopharmaceuticals / Dept. of Drug Design and Pharmacology
Faculty of Health and Medical Sciences (SUND)
University of Copenhagen

The Center for Biopharmaceuticals (Dept. of Drug Design and Pharmacology) is offering a three-year PhD fellowship in ion channel function and biophysics. The PhD fellowship is financed by the Carlsberg Foundation. The fellowship is available from 1 October 2017 or as soon as possible thereafter.

Project description
The PhD project will foc…

via http://ift.tt/1puljGF

Friday, 12 May 2017

Executive Research Director

Executive Research Director – Heptares Zurich

Heptares Therapeutics Ltd is clinical stage company using innovative techniques techniques in protein engineering and structure based drug design directed at G protein coupled receptors (GPCRs). Heptares has built an exciting pipeline of new medicines across disease areas including Alzheimer’s disease, migraine and cancer. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including …

via http://ift.tt/1puljGF

Tuesday, 9 May 2017

Drug Discovery Opportunities at D. E. Shaw Research

D. E. Shaw Research is seeking outstanding scientists with expertise in structure-based drug design or related areas to join our New York–based team. This is a unique opportunity to develop and work with transformative technology in a dynamic, interdisciplinary environment.

Areas relevant to our efforts include computer-aided drug design, fragment-based approaches, molecular modeling, cheminformatics and bioinformatics, medicinal chemistry, and target analysis and selection. Specific knowle…

via http://ift.tt/1puljGF

Wednesday, 8 March 2017

Scientist – Computer-Aided Drug Design (CADD)

As a major element of Roche Pharma Research and Early Development (Roche pRED), the Therapeutic Modalities (TMo) function is responsible for creating innovative drug candidates for all Roche pRED Discovery and Translational areas (DTAs), spanning small molecules, biologics and nucleic acid-based therapeutics. As part of TMo, the Chemical Biology (CB) department focuses on the success of Roche’s preclinical pipeline by delivering leading edge science through strong expertise in high-throughput, D…

via http://ift.tt/1puljGF